Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gion

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Clinical Chemistry|September 11, 1998
Tissue polypeptide antigen as a putative indicator of apoptosisR Dittadi, D Coradini, S Meo, et al.
British Journal of Cancer|May 1, 1991
The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 casesM Gion, R Mione, O Nascimben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2005
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlateG Gasparini, R Sarmiento, S Amici, et al.
The International Journal of Biological Markers|July 29, 1998
Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifenR Dittadi, E Biganzoli, P Boracchi, et al.
The International Journal of Biological Markers|July 27, 2001
Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartmentsR Dittadi, S Meo, F Fabris, et al.
The International Journal of Biological Markers|July 1, 1996
Cathepsin D versus other prognostic factors in breast cancer. Results and controversies of a multicenter study on 2575 casesD Pelizzola, M Gion, A Paradiso, et al.
Cell Proliferation|July 1, 1996
c-erbB-2/neu protein expression, DNA ploidy and S phase in breast cancerR Dittadi, F Calderazzo, A Cabrelle, et al.
Anticancer Research|March 1, 1997
ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative methodR Dittadi, A Brazzale, G Pappagallo, et al.
Gastroenterology|June 1, 1988
Tumor marker radioimmunoassays in gastric juice. Methodologic drawbacks due to pH variationsM Gion, R Dittadi, G Munegato, et al.
The International Journal of Biological Markers|April 1, 1994
The correlation between serum levels of cytokeratin tumor markers does reflect their molecular characterizationM Gion, R Mione, P Barioli, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Clinical Chemistry|September 11, 1998
Tissue polypeptide antigen as a putative indicator of apoptosisR Dittadi, D Coradini, S Meo, et al.
British Journal of Cancer|May 1, 1991
The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 casesM Gion, R Mione, O Nascimben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2005
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlateG Gasparini, R Sarmiento, S Amici, et al.
The International Journal of Biological Markers|July 29, 1998
Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifenR Dittadi, E Biganzoli, P Boracchi, et al.
The International Journal of Biological Markers|July 27, 2001
Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartmentsR Dittadi, S Meo, F Fabris, et al.
The International Journal of Biological Markers|July 1, 1996
Cathepsin D versus other prognostic factors in breast cancer. Results and controversies of a multicenter study on 2575 casesD Pelizzola, M Gion, A Paradiso, et al.
Cell Proliferation|July 1, 1996
c-erbB-2/neu protein expression, DNA ploidy and S phase in breast cancerR Dittadi, F Calderazzo, A Cabrelle, et al.
Anticancer Research|March 1, 1997
ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative methodR Dittadi, A Brazzale, G Pappagallo, et al.
Gastroenterology|June 1, 1988
Tumor marker radioimmunoassays in gastric juice. Methodologic drawbacks due to pH variationsM Gion, R Dittadi, G Munegato, et al.
The International Journal of Biological Markers|April 1, 1994
The correlation between serum levels of cytokeratin tumor markers does reflect their molecular characterizationM Gion, R Mione, P Barioli, et al.
Pageof 13